请输入您要查询的百科知识：

　

词条 Immunotherapy
释义

  1. Immunomodulators

  2. Activation immunotherapies

     Cancer  Dendritic cell-based pump-priming  T-cell adoptive transfer 

  3. Immune enhancement therapy

  4. Suppression immunotherapies

     Immunosuppressive drugs  Immune tolerance  Allergies 

  5. Helminthic therapies

  6. See also

  7. References

  8. External links

{{For|the academic journal|Immunotherapy (journal)}}{{medical citations needed|date=April 2018}}{{primary sources|date=April 2018}}{{Infobox medical intervention
| Name = Immunotherapy
| Image =
| Caption =
| ICD10 =
| ICD9unlinked =
| MeshID = D007167
| OPS301 = {{OPS301|8-03}}
| OtherCodes =
}}Immunotherapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies.

In recent years, immunotherapy has become of great interest to researchers, clinicians and pharmaceutical companies, particularly in its promise to treat various forms of cancer.[1][2]

Immunomodulatory regimens often have fewer side effects than existing drugs, including less potential for creating resistance when treating microbial disease.[3]

Cell-based immunotherapies are effective for some cancers. Immune effector cells such as lymphocytes, macrophages, dendritic cells, natural killer cells (NK Cell), cytotoxic T lymphocytes (CTL), etc., work together to defend the body against cancer by targeting abnormal antigens expressed on the surface of tumor cells.

Therapies such as granulocyte colony-stimulating factor (G-CSF), interferons, imiquimod and cellular membrane fractions from bacteria are licensed for medical use. Others including IL-2, IL-7, IL-12, various chemokines, synthetic cytosine phosphate-guanosine (CpG) oligodeoxynucleotides and glucans are involved in clinical and preclinical studies.

{{toclimit|3}}

Immunomodulators

Immunomodulators are the active agents of immunotherapy. They are a diverse array of recombinant, synthetic, and natural preparations.

Class Example agents
Interleukins IL-2, IL-7, IL-12
Cytokines Interferons, G-CSF
Chemokines CCL3, CCL26, CXCL7
Immunomodulatory imide drugs (IMiDs) thalidomide and its analogues (lenalidomide, pomalidomide, and apremilast)
Other cytosine phosphate-guanosine, oligodeoxynucleotides, glucans

Activation immunotherapies

Cancer

{{main|Cancer immunotherapy}}

Cancer immunotherapy attempts to stimulate the immune system to destroy tumors. A variety of strategies are in use or are undergoing research and testing. Randomized controlled studies in different cancers resulting in significant increase in survival and disease free period have been reported[2] and its efficacy is enhanced by 20–30% when cell-based immunotherapy is combined with conventional treatment methods.[2]

One of the oldest forms of cancer immunotherapy is the use of BCG vaccine, which was originally to vaccinate against tuberculosis and later was found to be useful in the treatment of bladder cancer.[4]

The extraction of G-CSF lymphocytes from the blood and expanding in vitro against a tumour antigen before reinjecting the cells with appropriate stimulatory cytokines. The cells then destroy the tumor cells that express the antigen.{{Citation needed|date=March 2013}}

Topical immunotherapy utilizes an immune enhancement cream (imiquimod) which produces interferon, causing the recipient's killer T cells to destroy warts,[5] actinic keratoses, basal cell cancer, vaginal intraepithelial neoplasia,[6] squamous cell cancer,[7][8] cutaneous lymphoma,[9] and superficial malignant melanoma.[10]

Injection immunotherapy ("intralesional" or "intratumoral") uses mumps, candida, the HPV vaccine[11][12] or trichophytin antigen injections to treat warts (HPV induced tumors).

Adoptive cell transfer has been tested on lung [13] and other cancers, with greatest success achieved in melanoma.

Dendritic cell-based pump-priming

Dendritic cells can be stimulated to activate a cytotoxic response towards an antigen. Dendritic cells, a type of antigen presenting cell, are harvested from the person needing the immunotherapy. These cells are then either pulsed with an antigen or tumor lysate or transfected with a viral vector, causing them to display the antigen. Upon transfusion into the person, these activated cells present the antigen to the effector lymphocytes (CD4+ helper T cells, cytotoxic CD8+ T cells and B cells). This initiates a cytotoxic response against tumor cells expressing the antigen (against which the adaptive response has now been primed). The cancer vaccine Sipuleucel-T is one example of this approach.[14]

T-cell adoptive transfer

Adoptive cell transfer in vitro cultivates autologous, extracted T cells for later transfusion.[15]

Alternatively, Genetically engineered T cells are created by harvesting T cells and then infecting the T cells with a retrovirus that contains a copy of a T cell receptor (TCR) gene that is specialised to recognise tumour antigens. The virus integrates the receptor into the T cells' genome. The cells are expanded non-specifically and/or stimulated. The cells are then reinfused and produce an immune response against the tumour cells.[16] The technique has been tested on refractory stage IV metastatic melanomas[15] and advanced skin cancer[17][18][19]

Whether T cells are genetically engineered or not, before reinfusion, lymphodepletion of the recipient is required to eliminate regulatory T cells as well as unmodified, endogenous lymphocytes that compete with the transferred cells for homeostatic cytokines.[15][20][21][22] Lymphodepletion may be achieved by myeloablative chemotherapy, to which total body irradiation may be added for greater effect.[23] Transferred cells multiplied in vivo and persisted in peripheral blood in many people, sometimes representing levels of 75% of all CD8+ T cells at 6–12 months after infusion.[24] As of 2012, clinical trials for metastatic melanoma were ongoing at multiple sites.[25] Clinical responses to adoptive transfer of T cells were observed in patients with metastatic melanoma resistant to multiple immunotherapies.[26]

Immune enhancement therapy

Autologous immune enhancement therapy use a person's own peripheral blood-derived natural killer cells, cytotoxic T lymphocytes and other relevant immune cells are expanded in vitro and then reinfused.[27] The therapy has been tested against Hepatitis C,[28][29][30] Chronic fatigue syndrome[31][32] and HHV6 infection.[33]

Suppression immunotherapies

Immune suppression dampens an abnormal immune response in autoimmune diseases or reduces a normal immune response to prevent rejection of transplanted organs or cells.

Immunosuppressive drugs

Immunosuppressive drugs help manage organ transplantation and autoimmune disease. Immune responses depend on lymphocyte proliferation. Cytostatic drugs are immunosuppressive. Glucocorticoids are somewhat more specific inhibitors of lymphocyte activation, whereas inhibitors of immunophilins more specifically target T lymphocyte activation. Immunosuppressive antibodies target steps in the immune response. Other drugs modulate immune responses.

Immune tolerance

{{Main|Immune tolerance}}

The body naturally does not launch an immune system attack on its own tissues. Immune tolerance therapies seek to reset the immune system so that the body stops mistakenly attacking its own organs or cells in autoimmune disease or accepts foreign tissue in organ transplantation.[34] Creating immunity reduces or eliminates the need for lifelong immunosuppression and attendant side effects. It has been tested on transplantations, and type 1 diabetes or other autoimmune disorders.

Allergies

{{main|Allergen immunotherapy}}

Immunotherapy is used to treat allergies. While allergy treatments (such as antihistamines or corticosteroids) treat allergic symptoms, immunotherapy can reduce sensitivity to allergens, lessening its severity.

Immunotherapy may produce long-term benefits.[35] Immunotherapy is partly effective in some people and ineffective in others, but it offers allergy sufferers a chance to reduce or stop their symptoms.

The therapy is indicated for people who are extremely allergic or who cannot avoid specific allergens. Immunotherapy is generally not indicated for food or medicinal allergies. This therapy is particularly useful for people with allergic rhinitis or asthma.

The first dose contain tiny amounts of the allergen or antigen. Dosages increase over time, as the person becomes desensitized. This technique has been tested on infants to prevent peanut allergies.[36]

Helminthic therapies

Whipworm ova (Trichuris suis) and Hookworm (Necator americanus) have been tested for immunological diseases and allergies. Helminthic therapy has been investigated as a treatment for relapsing remitting multiple sclerosis[37] Crohn’s,[38][39][40] allergies and asthma.[41] The mechanism of how the helminths modulate the immune response, is unknown. Hypothesized mechanisms include re-polarisation of the Th1 / Th2 response[42] and modulation of dendritic cell function.[43][44] The helminths down regulate the pro-inflammatory Th1 cytokines, Interleukin-12 (IL-12), Interferon-Gamma (IFN-γ) and Tumour Necrosis Factor-Alpha (TNF-ά), while promoting the production of regulatory Th2 cytokines such as IL-10, IL-4, IL-5 and IL-13.[42][45]

Co-evolution with helminths has shaped some of the genes associated with Interleukin expression and immunological disorders, such Crohn's, ulcerative colitis and celiac disease. Helminth's relationship to humans as hosts should be classified as mutualistic or symbiotic.{{Citation needed|date=April 2016}}

See also

  • Biological response modifiers
  • Checkpoint inhibitor
  • Interleukin-2 immunotherapy
  • Microtransplantation

References

1. ^{{Cite web|url=https://www.mskcc.org/cancer-care/diagnosis-treatment/cancer-treatments/immunotherapy|title=Immunotherapy {{!}} Memorial Sloan Kettering Cancer Center|website=www.mskcc.org|language=en|access-date=2017-07-27}}
2. ^1 2 {{cite journal | vauthors = Syn NL, Teng MW, Mok TS, Soo RA | title = De-novo and acquired resistance to immune checkpoint targeting | journal = The Lancet. Oncology | volume = 18 | issue = 12 | pages = e731-e741 | date = December 2017 | pmid = 29208439 | doi = 10.1016/s1470-2045(17)30607-1 }}
3. ^{{cite journal | author = Masihi KN | title = Fighting infection using immunomodulatory agents | journal = Expert Opin Biol Ther | volume = 1 | issue = 4 | pages = 641–53 |date=July 2001 | pmid = 11727500 | doi = 10.1517/14712598.1.4.641 }}
4. ^{{cite journal | vauthors = Fuge O, Vasdev N, Allchorne P, Green JS | title = Immunotherapy for bladder cancer | journal = Research and Reports in Urology | volume = 7 | pages = 65–79 | date = 2015 | pmid = 26000263 | pmc = 4427258 | doi = 10.2147/RRU.S63447 }}
5. ^{{cite journal |vauthors=van Seters M, van Beurden M, ten Kate FJ, Beckmann I, Ewing PC, Eijkemans MJ, Kagie MJ, Meijer CJ, Aaronson NK, Kleinjan A, Heijmans-Antonissen C, Zijlstra FJ, Burger MP, Helmerhorst TJ | title = Treatment of vulvar intraepithelial neoplasia with topical imiquimod | journal = N. Engl. J. Med. | volume = 358 | issue = 14 | pages = 1465–73 |date=April 2008 | pmid = 18385498 | doi = 10.1056/NEJMoa072685 }}
6. ^{{cite journal |vauthors=Buck HW, Guth KJ | title = Treatment of vaginal intraepithelial neoplasia (primarily low grade) with imiquimod 5% cream | journal = J Low Genit Tract Dis | volume = 7 | issue = 4 | pages = 290–3 |date=October 2003 | pmid = 17051086 | doi = 10.1097/00128360-200310000-00011 }}
7. ^{{cite journal |vauthors=Järvinen R, Kaasinen E, Sankila A, Rintala E | title = Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up | journal = Eur. Urol. | volume = 56 | issue = 2 | pages = 260–5 |date=August 2009 | pmid = 19395154 | doi = 10.1016/j.eururo.2009.04.009 }}
8. ^{{cite journal |vauthors=Davidson HC, Leibowitz MS, Lopez-Albaitero A, Ferris RL | title = Immunotherapy for head and neck cancer | journal = Oral Oncol. | volume = 45 | issue = 9 | pages = 747–51 |date=September 2009 | pmid = 19442565 | doi = 10.1016/j.oraloncology.2009.02.009 }}
9. ^{{cite journal |vauthors=Dani T, Knobler R | title = Extracorporeal photoimmunotherapy-photopheresis | journal = Front. Biosci. | volume = 14 | issue = 14| pages = 4769–77 | year = 2009 | pmid = 19273388 | doi = 10.2741/3566 }}
10. ^{{cite journal |vauthors=Eggermont AM, Schadendorf D | title = Melanoma and immunotherapy | journal = Hematol. Oncol. Clin. North Am. | volume = 23 | issue = 3 | pages = 547–64, ix–x |date=June 2009 | pmid = 19464602 | doi = 10.1016/j.hoc.2009.03.009 }}
11. ^{{cite journal |vauthors=Chuang CM, Monie A, Wu A, Hung CF | title = Combination of apigenin treatment with therapeutic HPV DNA vaccination generates enhanced therapeutic anti tumor effects | journal = J. Biomed. Sci. | volume = 16 | issue = 1| pages = 49 | year = 2009 | pmid = 19473507 | pmc = 2705346 | doi = 10.1186/1423-0127-16-49 }}
12. ^{{cite journal |vauthors=Pawlita M, Gissmann L | title = [Recurrent respiratory papillomatosis: indication for HPV vaccination?] | language = German | journal = Dtsch. Med. Wochenschr. | volume = 134 Suppl 2 | issue = | pages = S100–2 |date=April 2009 | pmid = 19353471 | doi = 10.1055/s-0029-1220219 }}
13. ^{{cite journal |vauthors=Kang N, Zhou J, Zhang T, Wang L, Lu F, Cui Y, Cui L, He W | title = Adoptive immunotherapy of lung cancer with immobilized anti-TCRgammadelta antibody-expanded human gammadelta T-cells in peripheral blood | journal = Cancer Biol. Ther. | volume = 8 | issue = 16 | pages = 1540–9 |date=August 2009 | pmid = 19471115 | doi = 10.4161/cbt.8.16.8950 }}
14. ^{{cite journal |vauthors=Di Lorenzo G, Buonerba C, Kantoff PW | title = Immunotherapy for the treatment of prostate cancer | journal = Nature Reviews Clinical Oncology | volume = 8 | issue = 9 | pages = 551–61 |date=September 2011 | pmid = 21606971 | doi = 10.1038/nrclinonc.2011.72 }}
15. ^1 2 {{cite journal |vauthors=Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME | title = Adoptive cell transfer: A clinical path to effective cancer immunotherapy | journal = Nature Reviews Cancer | volume = 8 | issue = 4 | pages = 299–308 |date=April 2008 | pmid = 18354418 | pmc = 2553205 | doi = 10.1038/nrc2355 }}
16. ^{{cite journal |vauthors=Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA | title = Cancer regression in patients after transfer of genetically engineered lymphocytes | journal = Science | volume = 314 | issue = 5796 | pages = 126–9 |date=October 2006 | pmid = 16946036 | pmc = 2267026 | doi = 10.1126/science.1129003 }}
17. ^{{cite journal |vauthors=Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, Jungbluth A, Gnjatic S, Thompson JA, Yee C | title = Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1 | journal = N. Engl. J. Med. | volume = 358 | issue = 25 | pages = 2698–703 |date=June 2008 | pmid = 18565862 | pmc = 3277288 | doi = 10.1056/NEJMoa0800251 }}
18. ^{{cite web | url = http://www.cancerresearch.org/events/symposium/cancer-immunology-immunotherapy-2008/program-speakers.html | title = 2008 Symposium Program & Speakers | website = | publisher = Cancer Research Institute | deadurl = yes | archiveurl = https://web.archive.org/web/20081015045915/http://www.cancerresearch.org/events/symposium/cancer-immunology-immunotherapy-2008/program-speakers.html | archivedate = 2008-10-15 }}
19. ^{{cite news | first = Roger | last = Highfield | name-list-format = vanc | title = Cancer patient recovers after injection of immune cells | url = https://www.telegraph.co.uk/earth/main.jhtml?xml=/earth/2008/06/18/scicanc118.xml | archive-url = https://web.archive.org/web/20080912063314/http://www.telegraph.co.uk/earth/main.jhtml?xml=/earth/2008/06/18/scicanc118.xml | archive-date = 12 September 2008 | dead-url = yes | date = 18 June 2008 | newspaper = The Telegraph }}
20. ^{{cite journal |vauthors=Antony PA, Piccirillo CA, Akpinarli A, Finkelstein SE, Speiss PJ, Surman DR, Palmer DC, Chan CC, Klebanoff CA, Overwijk WW, Rosenberg SA, Restifo NP | title = CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells | journal = Journal of Immunology | volume = 174 | issue = 5 | pages = 2591–601 |date=March 2005 | pmid = 15728465 | pmc = 1403291 | doi = 10.4049/jimmunol.174.5.2591}}
21. ^{{cite journal |vauthors=Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, Hwang LN, Yu Z, Wrzesinski C, Heimann DM, Surh CD, Rosenberg SA, Restifo NP | title = Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells | journal = J. Exp. Med. | volume = 202 | issue = 7 | pages = 907–12 |date=October 2005 | pmid = 16203864 | pmc = 1397916 | doi = 10.1084/jem.20050732 }}
22. ^{{cite journal |vauthors=Dummer W, Niethammer AG, Baccala R, Lawson BR, Wagner N, Reisfeld RA, Theofilopoulos AN | title = T cell homeostatic proliferation elicits effective antitumor autoimmunity | journal = J. Clin. Invest. | volume = 110 | issue = 2 | pages = 185–92 |date=July 2002 | pmid = 12122110 | pmc = 151053 | doi = 10.1172/JCI15175 }}
23. ^{{cite journal |vauthors=Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J, Morton K, Laurencot C, White DE, Rosenberg SA | title = Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens | journal = J. Clin. Oncol. | volume = 26 | issue = 32 | pages = 5233–9 |date=November 2008 | pmid = 18809613 | pmc = 2652090 | doi = 10.1200/JCO.2008.16.5449 }}
24. ^{{cite journal |vauthors=Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA | title = Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes | journal = Science | volume = 298 | issue = 5594 | pages = 850–4 |date=October 2002 | pmid = 12242449 | pmc = 1764179 | doi = 10.1126/science.1076514 }}
25. ^{{cite journal |vauthors=Pilon-Thomas S, Kuhn L, Ellwanger S, Janssen W, Royster E, Marzban S, Kudchadkar R, Zager J, Gibney G, Sondak VK, Weber J, Mulé JJ, Sarnaik AA | title = Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma | journal = J. Immunother. | volume = 35 | issue = 8 | pages = 615–20 |date=October 2012 | pmid = 22996367 | doi = 10.1097/CJI.0b013e31826e8f5f | pmc = 4467830 }}
26. ^{{cite journal |vauthors=Andersen R, Borch TH, Draghi A, Gokuldass A, Rana MA, Pedersen M, Nielsen M, Kongsted P, Kjeldsen JW, Westergaard MC, Radic HD, Chamberlain CA, Holmich LR, Hendel HW, Larsen MS, Met O, Svane IM, Donia M | title = T cells isolated from patients with checkpoint inhibitor resistant-melanoma are functional and can mediate tumor regression. | journal = Ann. Oncol. | volume = 29 | issue = 7 | pages = 1575–1581 | date=April 2018 | pmid = 29688262 | doi = 10.1093/annonc/mdy139 }}
27. ^{{cite journal |vauthors=Manjunath SR, Ramanan G, Dedeepiya VD, Terunuma H, Deng X, Baskar S, Senthilkumar R, Thamaraikannan P, Srinivasan T, Preethy S, Abraham SJ | title = Autologous immune enhancement therapy in recurrent ovarian cancer with metastases: a case report | journal = Case Rep. Oncol. | volume = 5 | issue = 1 | pages = 114–8 |date=January 2012 | pmid = 22666198 | pmc = 3364094 | doi = 10.1159/000337319 }}
28. ^{{cite journal |vauthors=Li Y, Zhang T, Ho C, Orange JS, Douglas SD, Ho WZ | title = Natural killer cells inhibit hepatitis C virus expression | journal = J. Leukoc. Biol. | volume = 76 | issue = 6 | pages = 1171–9 |date=December 2004 | pmid = 15339939 | doi = 10.1189/jlb.0604372 }}
29. ^{{cite journal |vauthors=Doskali M, Tanaka Y, Ohira M, Ishiyama K, Tashiro H, Chayama K, Ohdan H | title = Possibility of adoptive immunotherapy with peripheral blood-derived CD3⁻CD56+ and CD3+CD56+ cells for inducing antihepatocellular carcinoma and antihepatitis C virus activity | journal = J. Immunother. | volume = 34 | issue = 2 | pages = 129–38 |date=March 2011 | pmid = 21304407 | doi = 10.1097/CJI.0b013e3182048c4e }}
30. ^{{cite journal |vauthors=Terunuma H, Deng X, Dewan Z, Fujimoto S, Yamamoto N | title = Potential role of NK cells in the induction of immune responses: implications for NK cell-based immunotherapy for cancers and viral infections | journal = Int. Rev. Immunol. | volume = 27 | issue = 3 | pages = 93–110 | year = 2008 | pmid = 18437601 | doi = 10.1080/08830180801911743 }}
31. ^{{cite journal |vauthors=See DM, Tilles JG | title = alpha-Interferon treatment of patients with chronic fatigue syndrome | journal = Immunol. Invest. | volume = 25 | issue = 1–2 | pages = 153–64 | year = 1996 | pmid = 8675231 | doi = 10.3109/08820139609059298 }}
32. ^{{cite journal |vauthors=Ojo-Amaize EA, Conley EJ, Peter JB | title = Decreased natural killer cell activity is associated with severity of chronic fatigue immune dysfunction syndrome | journal = Clin. Infect. Dis. | volume = 18 Suppl 1 | issue = | pages = S157–9 |date=January 1994 | pmid = 8148445 | doi = 10.1093/clinids/18.Supplement_1.S157 }}
33. ^{{cite journal |vauthors=Kida K, Isozumi R, Ito M | title = Killing of human Herpes virus 6-infected cells by lymphocytes cultured with interleukin-2 or -12 | journal = Pediatr. Int. | volume = 42 | issue = 6 | pages = 631–6 |date=December 2000 | pmid = 11192519 | doi = 10.1046/j.1442-200x.2000.01315.x }}
34. ^{{cite journal |vauthors=Rotrosen D, Matthews JB, Bluestone JA | title = The immune tolerance network: a new paradigm for developing tolerance-inducing therapies | journal = The Journal of Allergy and Clinical Immunology | volume = 110 | issue = 1 | pages = 17–23 |date=July 2002 | pmid = 12110811 | doi = 10.1067/mai.2002.124258 }}
35. ^{{cite journal |vauthors=Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, Till SJ, Hamid QA, Nouri-Aria KT | title = Long-term clinical efficacy of grass-pollen immunotherapy | journal = N. Engl. J. Med. | volume = 341 | issue = 7 | pages = 468–75 |date=August 1999 | pmid = 10441602 | doi = 10.1056/NEJM199908123410702 }}
36. ^{{Cite web|url=http://med.stanford.edu/clinicaltrials/trials/search?condition=Food%2520Allergy|title=Clinical Trials Search Results - Stanford University School of Medicine|website=med.stanford.edu|access-date=2016-04-03}}
37. ^{{cite journal |vauthors=Correale J, Farez M | title = Association between parasite infection and immune responses in multiple sclerosis | journal = Annals of Neurology | volume = 61 | issue = 2 | pages = 97–108 |date=February 2007 | pmid = 17230481 | doi = 10.1002/ana.21067 }}
38. ^{{cite journal |vauthors=Croese J, O'neil J, Masson J, Cooke S, Melrose W, Pritchard D, Speare R | title = A proof of concept study establishing Necator americanus in Crohn's patients and reservoir donors | journal = Gut | volume = 55 | issue = 1 | pages = 136–7 |date=January 2006 | pmid = 16344586 | pmc = 1856386 | doi = 10.1136/gut.2005.079129 }}
39. ^{{cite journal |vauthors=Reddy A, Fried B | title = An update on the use of helminths to treat Crohn's and other autoimmunune diseases | journal = Parasitol. Res. | volume = 104 | issue = 2 | pages = 217–21 |date=January 2009 | pmid = 19050918 | doi = 10.1007/s00436-008-1297-5 }}
40. ^{{cite journal |vauthors=Laclotte C, Oussalah A, Rey P, Bensenane M, Pluvinage N, Chevaux JB, Trouilloud I, Serre AA, Boucekkine T, Bigard MA, Peyrin-Biroulet L | title = [Helminths and inflammatory bowel diseases] | language = French | journal = Gastroenterol. Clin. Biol. | volume = 32 | issue = 12 | pages = 1064–74 |date=December 2008 | pmid = 18619749 | doi = 10.1016/j.gcb.2008.04.030 }}
41. ^{{cite journal |vauthors=Zaccone P, Fehervari Z, Phillips JM, Dunne DW, Cooke A | title = Parasitic worms and inflammatory diseases | journal = Parasite Immunol. | volume = 28 | issue = 10 | pages = 515–23 |date=October 2006 | pmid = 16965287 | pmc = 1618732 | doi = 10.1111/j.1365-3024.2006.00879.x }}
42. ^1 {{cite book|doi=10.1016/S0065-308X(04)58004-1 |title=Human Hookworm Infection in the 21st Century |year=2004 |vauthors=Brooker S, Bethony J, Hotez PJ |isbn=9780120317585 |journal=Advances in Parasitology |volume=58 |pages=197–288 |pmid=15603764 |pmc=2268732 }}
43. ^{{cite journal | vauthors = Fujiwara RT, Cançado GG, Freitas PA, Santiago HC, Massara CL, Dos Santos Carvalho O, Corrêa-Oliveira R, Geiger SM, Bethony J | title = Necator americanus infection: a possible cause of altered dendritic cell differentiation and eosinophil profile in chronically infected individuals | journal = PLoS Negl. Trop. Dis. | volume = 3 | issue = 3 | pages = e399 | year = 2009 | pmid = 19308259 | pmc = 2654967 | doi = 10.1371/journal.pntd.0000399 | editor1-last = Yazdanbakhsh | editor1-first = Maria }}
44. ^{{cite journal |vauthors=Carvalho L, Sun J, Kane C, Marshall F, Krawczyk C, Pearce EJ | title = Review series on helminths, immune modulation and the hygiene hypothesis: mechanisms underlying helminth modulation of dendritic cell function | journal = Immunology | volume = 126 | issue = 1 | pages = 28–34 |date=January 2009 | pmid = 19120496 | pmc = 2632707 | doi = 10.1111/j.1365-2567.2008.03008.x }}
45. ^{{cite journal |vauthors=Fumagalli M, Pozzoli U, Cagliani R, Comi GP, Riva S, Clerici M, Bresolin N, Sironi M | title = Parasites represent a major selective force for interleukin genes and shape the genetic predisposition to autoimmune conditions | journal = J. Exp. Med. | volume = 206 | issue = 6 | pages = 1395–408 |date=June 2009 | pmid = 19468064 | pmc = 2715056 | doi = 10.1084/jem.20082779 }}

External links

  • {{cite news|last1=Langreth|first1=Robert | name-list-format = vanc |title=Cancer Miracles|url=https://www.forbes.com/forbes/2009/0302/074_cancer_miracles.html|work=Forbes|date=12 February 2009}}
  • International Society for Biological Therapy of Cancer
  • Cancer Research Institute Annual International Cancer Immunotherapy Symposia Series
{{Portal bar|Biology|Medicine}}{{Authority control}}

3 : Immunotherapy|Cancer treatments|Virotherapy
随便看

　

开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。

　

Copyright © 2023 OENC.NET All Rights Reserved
京ICP备2021023879号 更新时间：2024/11/13 11:33:42